Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01106625




Registration number
NCT01106625
Ethics application status
Date submitted
1/04/2010
Date registered
20/04/2010
Date last updated
20/06/2013

Titles & IDs
Public title
The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)
Scientific title
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sulphonylurea Therapy
Secondary ID [1] 0 0
28431754DIA3002
Secondary ID [2] 0 0
CR017005
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Diabetes Mellitus, Type 2 0 0
Condition category
Condition code
Metabolic and Endocrine 0 0 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Canagliflozin
Treatment: Drugs - Placebo
Treatment: Drugs - Metformin
Treatment: Drugs - Sulphonylruea

Experimental: Canagliflozin 100 mg - Each patient will receive 100 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.

Experimental: Canagliflozin 300 mg - Each patient will receive 300 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.

Placebo Comparator: Placebo - Each patient will receive matching placebo once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.


Treatment: Drugs: Canagliflozin
One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.

Treatment: Drugs: Placebo
One matching placebo capsule orally once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.

Treatment: Drugs: Metformin
The patient's stable dose of background metformin therapy should be continued throughout the study.

Treatment: Drugs: Sulphonylruea
The patient's stable dose of background sulphonylurea therapy should be continued throughout the study.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change in HbA1c From Baseline to Week 26
Timepoint [1] 0 0
Day 1 (Baseline) and Week 26
Secondary outcome [1] 0 0
Percentage of Patients With HbA1c <7% at Week 26
Timepoint [1] 0 0
Week 26
Secondary outcome [2] 0 0
Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26
Timepoint [2] 0 0
Day 1 (Baseline) and Week 26
Secondary outcome [3] 0 0
Percent Change in Body Weight From Baseline to Week 26
Timepoint [3] 0 0
Day 1 (Baseline) and Week 26
Secondary outcome [4] 0 0
Change in Systolic Blood Pressure (SBP) From Baseline to Week 26
Timepoint [4] 0 0
Day 1 (Baseline) and Week 26
Secondary outcome [5] 0 0
Percent Change in Triglycerides From Baseline to Week 26
Timepoint [5] 0 0
Day 1 (Baseline) and Week 26
Secondary outcome [6] 0 0
Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26
Timepoint [6] 0 0
Day 1 (Baseline) and Week 26

Eligibility
Key inclusion criteria
- All patients must have a diagnosis of T2DM and be currently treated with metformin and
sulphonylurea

- Patients in the study must have a HbA1c between >=7 and <=10.5%

- Patients must have a fasting plasma glucose (FPG) <270 mg/dL (15 mmol/L)
Minimum age
18 Years
Maximum age
80 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta
cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy, or a
severe hypoglycemic episode within 6 months before screening

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/05/2010
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/04/2012
Sample size
Target
Accrual to date
Final
469
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
- Freemantle
Recruitment hospital [2] 0 0
- Heidelberg Heights
Recruitment hospital [3] 0 0
- Meadowbrook
Recruitment hospital [4] 0 0
- Nedlands
Recruitment hospital [5] 0 0
- Wollongong
Recruitment postcode(s) [1] 0 0
- Freemantle
Recruitment postcode(s) [2] 0 0
- Heidelberg Heights
Recruitment postcode(s) [3] 0 0
- Meadowbrook
Recruitment postcode(s) [4] 0 0
- Nedlands
Recruitment postcode(s) [5] 0 0
- Wollongong
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Alaska
Country [3] 0 0
United States of America
State/province [3] 0 0
Arizona
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Kentucky
Country [10] 0 0
United States of America
State/province [10] 0 0
Louisiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Maryland
Country [12] 0 0
United States of America
State/province [12] 0 0
Mississippi
Country [13] 0 0
United States of America
State/province [13] 0 0
Missouri
Country [14] 0 0
United States of America
State/province [14] 0 0
New York
Country [15] 0 0
United States of America
State/province [15] 0 0
North Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Ohio
Country [17] 0 0
United States of America
State/province [17] 0 0
Oklahoma
Country [18] 0 0
United States of America
State/province [18] 0 0
Oregon
Country [19] 0 0
United States of America
State/province [19] 0 0
Pennsylvania
Country [20] 0 0
United States of America
State/province [20] 0 0
South Carolina
Country [21] 0 0
United States of America
State/province [21] 0 0
Texas
Country [22] 0 0
United States of America
State/province [22] 0 0
Utah
Country [23] 0 0
United States of America
State/province [23] 0 0
Vermont
Country [24] 0 0
United States of America
State/province [24] 0 0
Washington
Country [25] 0 0
Belgium
State/province [25] 0 0
Aalst
Country [26] 0 0
Belgium
State/province [26] 0 0
Bonheiden
Country [27] 0 0
Belgium
State/province [27] 0 0
Edegem
Country [28] 0 0
Belgium
State/province [28] 0 0
Leuven
Country [29] 0 0
France
State/province [29] 0 0
Corbeil Essonnes
Country [30] 0 0
France
State/province [30] 0 0
La Rochelle
Country [31] 0 0
France
State/province [31] 0 0
Le Creusot
Country [32] 0 0
France
State/province [32] 0 0
Poitiers
Country [33] 0 0
France
State/province [33] 0 0
Venissieux
Country [34] 0 0
Guatemala
State/province [34] 0 0
Guatemala
Country [35] 0 0
Hungary
State/province [35] 0 0
Balatonfured
Country [36] 0 0
Hungary
State/province [36] 0 0
Budapest
Country [37] 0 0
Hungary
State/province [37] 0 0
Gyor
Country [38] 0 0
Hungary
State/province [38] 0 0
Zalaegerszeg
Country [39] 0 0
Israel
State/province [39] 0 0
Haifa
Country [40] 0 0
Israel
State/province [40] 0 0
Holon
Country [41] 0 0
Israel
State/province [41] 0 0
Jerusalem
Country [42] 0 0
Israel
State/province [42] 0 0
Tel Aviv
Country [43] 0 0
Mexico
State/province [43] 0 0
Guadalajara
Country [44] 0 0
Mexico
State/province [44] 0 0
Monterrey
Country [45] 0 0
Puerto Rico
State/province [45] 0 0
Carolina
Country [46] 0 0
Puerto Rico
State/province [46] 0 0
Trujillo Alto
Country [47] 0 0
Russian Federation
State/province [47] 0 0
Arkhangelsk
Country [48] 0 0
Russian Federation
State/province [48] 0 0
Saint Petersburg
Country [49] 0 0
Russian Federation
State/province [49] 0 0
Samara
Country [50] 0 0
Spain
State/province [50] 0 0
Alicante
Country [51] 0 0
Spain
State/province [51] 0 0
Almeria
Country [52] 0 0
Spain
State/province [52] 0 0
Malaga
Country [53] 0 0
Spain
State/province [53] 0 0
Sevilla
Country [54] 0 0
Spain
State/province [54] 0 0
Valencia
Country [55] 0 0
United Kingdom
State/province [55] 0 0
Belfast
Country [56] 0 0
United Kingdom
State/province [56] 0 0
Bolton
Country [57] 0 0
United Kingdom
State/province [57] 0 0
Liverpool
Country [58] 0 0
United Kingdom
State/province [58] 0 0
Manchester

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Janssen Research & Development, LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate the efficacy and safety of 2 different doses of
canagliflozin compared with placebo in patients with type 2 diabetes mellitus who are
receiving treatment with metformin and sulphonylurea and have inadequate glycemic (blood
sugar) control.
Trial website
https://clinicaltrials.gov/ct2/show/NCT01106625
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Janssen Research & Development, LLC C. Clinical Trial
Address 0 0
Janssen Research & Development, LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT01106625